Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19337454 | 0.80 | ALDH1A1 (0.46) | HTTALDH1A1TSHRRAB9A | |
| SCHEMBL29954086 | 0.79 | CA12 (0.42) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL9195863 | 0.79 | CA12 (0.44) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL27854759 | 0.78 | APP (0.44) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL27469486 | 0.78 | PYCR1 (0.39) | MEN1KMT2AHTTTAAR1ALDH1A1 | |
| SCHEMBL2552222 | 0.78 | APP (0.44) | MEN1KMT2ATAAR1ALDH1A1RAB9A | |
| SCHEMBL27675658 | 0.78 | CYP2A6 (0.30) | — | |
| SCHEMBL22137457 | 0.78 | CA12 (0.44) | CA12CA2CA9MEN1KMT2A | |
| SCHEMBL29953473 | 0.78 | HTR7 (0.43) | MEN1KMT2AHTTALDH1A1GLA | |
| SCHEMBL27913496 | 0.78 | NPC1 (0.47) | CA12CA2CA9MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044083-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2009-04-08 | — | — | EP | claimed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | claimed |
| WO-2008008912-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| WO-2008008907-A2 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. (US) | 2008-01-17 | — | — | WO | claimed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | claimed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | claimed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | claimed |
| CN-118271387-A | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2024-07-02 | — | — | CN | disclosed |
| CN-117946202-A | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-111770929-B | Compositions and methods for treating CNS disorders | 萨奇治疗股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| EP-2890698-B1 | DIOXINO- AND OXAZIN-[2,3-D]PYRIMIDINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-8475981-B2 | Image holding member for image forming apparatus, process cartridge, and image forming apparatus | FUJI XEROX, CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-20120015290-A1 | IMAGE HOLDING MEMBER FOR IMAGE FORMING APPARATUS, PROCESS CARTRIDGE, AND IMAGE FORMING APPARATUS | FUJI XEROX CO., LTD. (JP) | 2012-01-19 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | GENELABS TECHNOLOGIES, INC. | 2008-02-21 | — | — | US | disclosed |
| EP-1844042-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2007-10-17 | — | — | EP | disclosed |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | GENELABS, INC. | 2006-09-21 | — | — | US | disclosed |
| WO-2006076529-A1 | INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2006-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045498-A1 | POLYCYCLIC VIRAL INHIBITORS | EIF2AK2, ZC3HAV1, MAVS | CA12 3129/4885CA2 3882/4885CA9 2509/4885 |
| US-20060211698-A1 | Bicyclic heteroaryl derivatives for treating viruses | HAVCR2, ZC3HAV1, SARS1 | CA12 4098/4885CA2 4677/4885CA9 3903/4885 |
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | CA12 3926/4885CA2 4389/4885CA9 2980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.